Our data suggests intranasal delivery of thyroid hormones is not a suitable therapeutic strategy for MCT8 deficiency, although alternative formulations could be considered in the future to improve the nose-to-brain transport. The gene discussed is SLC16A2; the disease is hyperinsulinemic hypoglycemia, familial, 4.